129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Recruiting
Phase 2
Interventional Study
Pulmonary Arterial Hypertension
Idiopathic Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)
Connective Tissue Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 20 (estimated)
- Sponsor
- Bastiaan Driehuys · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Arm 1 -IPAH
* Age: 18-75 years
* WHO functional class 2 or 3
* Mean pulmonary artery pressures \> 20 mmHg
* Pulmonary capillary wedge pressure ≤15 mmHg
* Pulmonary vascular resistance \> 2 Wood Units (WU)
* No other cause identified for PAH
Arm 2 -PAH-CTD
* Age: 18-75 years
*…
Contacts